Big Tech Earnings On Deck… And President Trump Signs GENIUS Act 7/18/25
CNBC's "Fast Money"
00:00
Sarepta Therapeutics Faces Crisis Amid FDA Action and Stock Plummet
This chapter examines Sarepta Therapeutics' stock plummet after a patient's death is connected to its gene therapy drug, Elevitus. It also discusses the FDA's intervention and experts' insights on the management's credibility and the future risks tied to its key drug.
Transcript
Play full episode
